(USD M) | Jul'22 | Oct'22 | Jan'23 | Apr'23 | Jul'23 | Oct'23 | Jan'24 | Apr'24 | Jul'24 | Oct'24 |
---|---|---|---|---|---|---|---|---|---|---|
LTM Revenue % growth | 0.0 (55.0%) | 0.0 (55.0%) | 0.0 (63.1%) | 5.2 35,731.1% | 5.1 50,914.0% | 5.2 50,952.6% | 5.2 55,426.9% | 0.0 (99.6%) | 0.0 (99.6%) | 0.0 (99.7%) |
LTM NOPAT % growth | (5.8) N/A | (6.7) 14.7% | (6.8) 1.7% | (6.3) (6.2%) | (6.1) (3.2%) | (6.1) (1.1%) | (6.3) 3.0% | (6.6) 5.2% | (7.3) 10.8% | (7.5) 2.3% |
Discount rate | 6.1% | 11.0% | 9.8% | 9.0% | 9.6% | 8.3% | 10.7% | 11.5% | 8.7% | 11.2% |
Earnings Power Value (EPV) | (95.4) | (60.2) | (69.2) | (70.3) | (64.2) | (73.5) | (58.4) | (57.3) | (83.5) | (66.7) |
Enterprise Value (EV) | 13.7 | 16.9 | 18.3 | 8.7 | 8.9 | 3.7 | 9.2 | 0.5 | (1.8) | 2,923.3 |
Market-Implied Value of Growth (MIVoG) | 109.1 | 77.1 | 87.5 | 79.0 | 73.1 | 77.1 | 67.6 | 57.8 | 81.7 | 2,990.1 |
EPV as % of EV | (697.9%) | (356.9%) | (379.2%) | (805.4%) | (720.6%) | (1,996.4%) | (637.9%) | (11,351.5%) | 4,656.9% | (2.3%) |
MIVoG as % of EV | 797.9% | 456.9% | 479.2% | 905.4% | 820.6% | 2,096.4% | 737.9% | 11,451.5% | (4,556.9%) | 102.3% |
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
As of Oct 31, 2024, Heart Test Laboratories, Inc.'s Earnings Power Value is approximately ($66.7M).
As of Oct 31, 2024, Heart Test Laboratories, Inc.'s Enterprise Value (EV) estimates at $2,923.3M.
As of Oct 31, 2024, Heart Test Laboratories, Inc.'s Net operating profit after tax (NOPAT) is approximately ($7,466.1K).